Background: Venovenous extracorporeal membrane oxygenation (VV-ECMO) for select adults with severe acute respiratory distress syndrome (ARDS) cause by coronavirus disease 2019 (COVID-19) infection is a guideline-supported therapy with associated hospital survival of 62%–74%, similar to expected survival with VV-ECMO for other indications. However, ECMO is a resource-heavy intervention, and these patients often require long ECMO runs and prolonged intensive care unit (ICU) care. Identifying factors associated with mortality in VV-ECMO patients with COVID-19 infection can inform the evaluation of ECMO candidates as well as prognostication for those patients on prolonged VV-ECMO.

中文翻译：

---

接受静脉体外膜氧合治疗 COVID-19 急性呼吸窘迫综合征患者的死亡风险因素

背景：静脉体外膜肺氧合 (VV-ECMO) 用于治疗由 2019 年冠状病毒病 (COVID-19) 感染引起的严重急性呼吸窘迫综合征 (ARDS) 的选定成人是一种指南支持的治疗方法，相关住院生存率为 62%–74% ，与其他适应症的 VV-ECMO 预期生存期相似。然而，ECMO 是一种资源繁重的干预措施，这些患者通常需要长时间的 ECMO 运行和长时间的重症监护病房 (ICU) 护理。确定与 COVID-19 感染的 VV-ECMO 患者死亡率相关的因素可以为 ECMO 候选者的评估以及那些长期 VV-ECMO 患者的预后提供信息。